Skip to content

Journal of Psychopharmacology

ISSN 0269-8811, 1461-7285

521 papers in the library · 34,708 citations · publishing 1992-2026

Papers

Sort Most recent Most cited

Salvia divinorum use and phenomenology: results from an online survey.

Journal of Psychopharmacology November 1, 2011 Harry Sumnall, Fiona Measham, Simon D. Brandt et al. 38 citations

Salvia divinorum is a hallucinogenic plant with ethnopharmacological and recreational uses. It differs from classic serotonergic hallucinogens such as LSD and psilocin in both phenomenology and potent agonist activity of the active component salvinorin A at κ-opioid receptors. Awareness of S. divinorum has grown recently, with both an increase in its public representation and concern over its...

DOI: 10.1177/0269881110385596 (opens in new tab) Full text (opens in new tab) Salvia divinorum Hallucinogenic plant Psychoactive plant User experiences +15

Association of study characteristics with estimates of effect size in studies of ecstasy use.

Journal of Psychopharmacology November 2011 Eleanor M Taylor, Natasha M P Greene, Celia J. A. Morgan et al.

Studies of the chronic effects of MDMA, or 'ecstasy', in humans have been largely inconsistent. We explored whether study-level characteristics are associated with the effect size estimate reported. We based our analyses on the recent systematic review by Rogers and colleagues, focusing on those meta-analyses within this report where there was a relatively large number of studies contributing...

Pharmacogenetic studies of change in cortisol on ecstasy (MDMA) consumption

Journal of Psychopharmacology October 3, 2011 Kim Wolff, Eva-Maria Tsapakis, Carmine Maria Pariante et al. 37 citations

In this study we investigate the association of cytochrome P450 enzyme CYP2D6, catechol-O-methyl transferase (COMT, Val158Met) and serotonin transporter promoter (5-HTTLPR) genotypes on change in cortisol concentration following 3, 4-methylenedioxy-methamphetamine (MDMA, 'ecstasy') consumption. Forty-eight subjects (30 males, mean age 23 years), self-nominating regular clubbers provided 'in the...

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

Journal of Psychopharmacology September 28, 2011 Katherine A Maclean, Matthew W Johnson, Roland R. Griffiths 907 citations

A large body of evidence, including longitudinal analyses of personality change, suggests that core personality traits are predominantly stable after age 30. To our knowledge, no study has demonstrated changes in personality in healthy adults after an experimentally manipulated discrete event. Intriguingly, double-blind controlled studies have shown that the classic hallucinogen psilocybin...

History of cannabis use is not associated with alterations in striatal dopamine D 2 /D 3 receptor availability

Journal of Psychopharmacology September 2, 2011 Paul R A Stokes, Alice Egerton, Ben Watson et al. 62 citations

Cannabis use in adolescence is emerging as a risk factor for the development of psychosis. In animal studies, Δ9-tetrahydrocannabinol (THC), the psychoactive component of cannabis, modulates striatal dopaminergic neurotransmission. Alterations in human striatal dopaminergic function have also been reported both in psychosis and in stimulant use. We sought to examine whether striatal dopamine...

DOI: 10.1177/0269881111414090 (opens in new tab) Cannabis Raclopride Dopaminergic Striatum +3

Novel object recognition memory: measurement issues and effects of MDMA self-administration following short inter-trial intervals.

Journal of Psychopharmacology August 2011 Susan Schenk, David N. Harper, Jennifer Do

The present study was undertaken to examine effects of self-administered MDMA on novel object exploration (NOR) memory. Self-administration was conducted during daily 2 h tests that continued until a total of 165 mg/kg was self-administered (range = 13-41 days for individual rats). Control rats were placed in the self-administration boxes during daily sessions but did not receive any drug. One...

MDMA intoxication and verbal memory performance: a placebo-controlled pharmaco-MRI study

Journal of Psychopharmacology May 26, 2011 Kim P. C. Kuypers, Marleen Wingen, Armin Heinecke et al. 19 citations

The aim of the present study was to identify the neural substrate underlying memory impairment due to a single dose of MDMA (3,4-methylenedioxymethamphetamine) by means of pharmaco-MRI. Based on previous behavioral results it was hypothesized that this deficit could be attributed to a specific influence of MDMA on encoding. Fourteen Ecstasy users participated in this double-blind,...

The A2a adenosine receptor modulates the reinforcement efficacy and neurotoxicity of MDMA

Journal of Psychopharmacology January 24, 2011 Jéssica Ruiz‐medina, Catherine Ledent, Olga Carretón et al. 33 citations

Adenosine is an endogenous purine nucleoside that plays a neuromodulatory role in the central nervous system. A2a adenosine receptors have been involved in reward-related processes, inflammatory phenomena and neurotoxicity reactions. In the present study, we investigated the role of A2a adenosine receptors on the acute pharmacological effects, reinforcement and neuroinflammation induced by MDMA...

DOI: 10.1177/0269881110389210 (opens in new tab) MDMA Neurotoxicity Adenosine a2a receptor Pharmacology +6

Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice

Journal of Psychopharmacology December 8, 2010 Liselore Koedood, Adam L. Halberstadt, Susan B Powell et al. 212 citations

Psilocin (4-hydroxy- N, N-dimethyltryptamine) is a hallucinogen that acts as an agonist at 5-HT 1A , 5-HT 2A , and 5-HT 2C receptors. Psilocin is the active metabolite of psilocybin, a hallucinogen that is currently being investigated clinically as a potential therapeutic agent. In the present investigation, we used a combination of genetic and pharmacological approaches to identify the...

Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers.

Journal of Psychopharmacology November 2010 K A Wesnes, P Annas, C J Edgar et al.

This was a double-blind, randomised, placebo-controlled, crossover study of the acute cognitive and subjective effects of nabilone 1-3 mg in healthy male volunteers. The Cognitive Drug Research computerised system (CDR system) was used to assess changes in attention, working and episodic memory. In addition, a number of self-ratings were conducted including those of mood, alertness and...

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies

Journal of Psychopharmacology September 20, 2010 Erich Studerus, Michael Kometer, Felix Hasler et al. 529 citations

Psilocybin and related hallucinogenic compounds are increasingly used in human research. However, due to limited information about potential subjective side effects, the controlled medical use of these compounds has remained controversial. We therefore analysed acute, short- and long-term subjective effects of psilocybin in healthy humans by pooling raw data from eight double-blind...

Instability of the ecstasy market and a new kid on the block: mephedrone

Journal of Psychopharmacology September 8, 2010 Tibor M Brunt, Anneke Poortman, Raymond J.m. Niesink et al. 217 citations

Recently, several reports have indicated instability of the ecstasy market in the Netherlands and other EU countries. In the current study, we demonstrate this instability in the Netherlands, showing a decrease of ecstasy tablets containing 3,4-methylenedioxymetamphetamine (MDMA) by more than 50% in 2009. In addition, we describe a partial replacement of MDMA in tablets sold as ecstasy by a...

Acute psychomotor, memory and subjective effects of MDMA and THC co-administration over time in healthy volunteers

Journal of Psychopharmacology September 3, 2010 Gjh Dumont, J. G. Coen van Hasselt, M. de Kam et al. 38 citations

In Western societies a considerable percentage of young people expose themselves to the combination of 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’) and cannabis. The aim of the present study was to assess the acute effects of co-administration of MDMA and THC (the main psychoactive compound of cannabis) on pharmacokinetics, psychomotor performance, memory and subjective experience over...

mCPP: an undesired addition to the ecstasy market.

Journal of Psychopharmacology September 2010 Matthijs G. Bossong, Tibor M Brunt, J P Van Dijk et al.

A new ecstasy-like substance, meta-chlorophenylpiperazine (mCPP), has been detected in street drugs in the Netherlands. Theoretically, mCPP possesses the potential to become a non-neurotoxic alternative for methylenedioxymethamphetamine (MDMA), the regular psychoactive substance of ecstasy. Since its introduction on the Dutch market of synthetic drugs, the percentage of mCPP-containing tablets...

The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.

Journal of Psychopharmacology July 19, 2010 Michael C Mithoefer, Mark T Wagner, Ann T Mithoefer et al. 672 citations

Case reports indicate that psychiatrists administered ±3,4-methylenedioxymethamphetamine (MDMA) as a catalyst to psychotherapy before recreational use of MDMA as 'Ecstasy' resulted in its criminalization in 1985. Over two decades later, this study is the first completed clinical trial evaluating MDMA as a therapeutic adjunct. Twenty patients with chronic posttraumatic stress disorder,...

Effects of delta9-tetrahydrocannabinol on reward and anxiety in rats exposed to chronic unpredictable stress.

Journal of Psychopharmacology May 2010 S Fokos, G Panagis

Although cannabis derivatives produce clear subjective motivational responses in humans leading to drug-seeking behaviour, the reinforcing attributes of these subjective effects are difficult to define in experimental animals. The aim of this study was to examine how exposure to chronic unpredictable stress (CUS) will affect reward function and anxiety after acute administration of...

Effects of subchronic phencyclidine on behaviour of female rats on the elevated plus maze and open field.

Journal of Psychopharmacology May 2010 S L McLean, M L Woolley, J C Neill

Female hooded-Lister rats received either subchronic phencyclidine (PCP) (2 mg/kg, n = 20) or vehicle (1 ml/kg, n = 20) intraperitoneally twice daily for 7 days, followed by a 7-day washout period. Rats were challenged with acute PCP or vehicle and tested for locomotor activity to ensure hyperactivity was observed in the subchronic PCP-treated rats. Rats were then tested on the elevated plus...

The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability

Journal of Psychopharmacology April 15, 2010 Ben Sessa, Amanda Feilding, Robin Carhart-Harris et al. 53 citations

This study sought to assess the tolerability of intravenously administered psilocybin in healthy, hallucinogen-experienced volunteers in a mock-magnetic resonance imaging environment as a preliminary stage to a controlled investigation using functional magnetic resonance imaging to explore the effects of psilocybin on cerebral blood flow and activity. The present pilot study demonstrated that...

DOI: 10.1177/0269881110367445 (opens in new tab) Psilocybin Hallucinogen Tolerability Magnetic resonance imaging +2

NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test.

Journal of Psychopharmacology April 2010 M Ghasemi, M Raza, A R Dehpour

Although there is evidence of the involvement of N-methyl-D-aspartate receptors (NMDAR) in the action of lithium, its role in the antidepressant effects of lithium in a behavioural model remains unclear. In this study, we evaluated the effects of NMDAR antagonists on the antidepressant-like effects of lithium in the mouse forced swimming test. Lithium (30 and 100 mg/kg, i.p.) significantly (P <...

Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625.

Journal of Psychopharmacology March 2010 Lineke Zuurman, Christine Roy, R C Schoemaker et al.

CB1 antagonists such as AVE1625 are potentially useful in the treatment of obesity, smoking cessation and cognitive impairment. Proof of pharmacological action of AVE1625 in the brain can be given by antagonising the effects of delta-9-tetrahydrocannabinol (THC), a CB1/CB2 agonist. Inhibition of THC-induced effects by AVE1625 was observed on Visual Analogue Scales 'alertness', 'feeling high',...

Ecstasy (MDMA) and high prevalence psychiatric symptomatology: somatic anxiety symptoms are associated with polydrug, not ecstasy, use

Journal of Psychopharmacology February 1, 2010 G. Bedi, NT Van Dam, J. Redman

Although previous studies have examined anxiety and depression in ecstasy (±3,4-methylenedioxymethamphetamine; MDMA) users, it remains unclear whether symptoms are associated specifically with ecstasy or with polydrug use in general. We compared mean symptomatology and clinically significant symptoms in 45 ecstasy polydrug, 48 cannabis polydrug and 40 legal drug users, who completed...

Is emotional intelligence impaired in ecstasy-polydrug users?

Journal of Psychopharmacology February 2010 L Craig, John E. Fisk, C Montgomery et al.

Previous findings report use of the drug ecstasy (MDMA) to be associated with lower emotional intelligence (EI), and compromised functioning in brain areas responsible for emotion. This study explored the relationship between ecstasy use, EI, mood and parenting styles. Questionnaire measures of drug use, lifestyle, parenting style and EI were obtained, with separate IQ measures for fluid...

Ethanol-like effects of thiopental and ketamine in healthy humans

Journal of Psychopharmacology February 1, 2010 D. Dickerson, Brian Pittman, E. Ralevski et al.

The γ-aminobutyric acid-A (GABA A ) and N-methyl-D-aspartate (NMDA) receptors mediate aspects of the behavioural effects of alcohol. Prior studies reported drugs that block NMDA receptors or facilitate GABA A receptor function produce ethanol-like effects in humans. The purpose of this study was to compare the ethanol-related effects of two pharmacological agents with known NMDA and GABA A...

Harms associated with psychoactive substances: findings of the UK National Drug Survey

Journal of Psychopharmacology November 25, 2009 Celia J. A. Morgan, Leslie Muetzelfeldt, Mark Muetzelfeldt et al. 80 citations

Nutt and colleagues' 'rational' scale to assess the harms of commonly used drugs was based on ratings by a panel of experts. This survey aimed to assess drug users' views of the harms of drugs using the same scale. As users' drug choices are not solely based on harms, we additionally assessed perceived benefits. The survey was hosted at http://www.nationaldrugsurvey.org. UK residents reported...